Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-1186 in Diabetic Peripheral Neuropathic Pain
NCT07159243Phase 2Not yet recruiting
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of HL-1186 in diabetic polyneuropathy (DPN), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Change in Average Daily Pain Score at 12 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
HL-1186
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT07159243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159243.